BACKGROUND: Despite advances in pharmacotherapy of lipid disorders, many dyslipidemic patients do not attain sufficient lipid lowering to mitigate risk of atherosclerotic cardiovascular disease. Several classes of novel lipid-lowering agents are being evaluated to reduce atherosclerotic cardiovascular disease risk. Lipoprotein apheresis (LA) is effective in acutely lowering the plasma concentrations of atherogenic lipoproteins including low-density lipoprotein cholesterol and lipoprotein(a), and novel lipid-lowering drugs may dampen the lipid rebound effect of LA, with the possibility that LA frequency may be decreased, in some cases even be discontinued. SOURCES OF MATERIAL: This document builds on current American Society for Apheresis guidelines and, for the first time, makes recommendations from summarized data of the emerging lipid-lowering drug classes (inhibitors of proprotein convertase subtilisin/kexin type 9 or microsomal triglyceride transfer protein, high-density lipoprotein mimetic), including the available evidence on combination therapy with LA with respect to the management of patients with dyslipidemia. ABSTRACT OF FINDINGS: Recommendations for different indications are given based on the latest evidence. However, except for lomitapide in homozygous familial hypercholesterolemia and alirocumab/ evolocumab in heterozygous familial hypercholesterolemia subjects, limited data are available on the effectiveness and safety of combination therapy. More studies on combining LA with novel lipid-lowering drugs are needed. CONCLUSION: Novel lipid-lowering agents have potential to improve the performance of LA, but more evidence is needed. The Multidisciplinary International Group for Hemapheresis TherapY and Metabolic DIsturbances Contrast scientific society aims to establish an international registry of clinical experience on LA combination therapy to expand the evidence on this treatment in individuals at high cardiovascular disease risk.

BACKGROUND: Despite advances in pharmacotherapy of lipid disorders, many dyslipidemic patients do not attain sufficient lipid lowering to mitigate risk of atherosclerotic cardiovascular disease. Several classes of novel lipid-lowering agents are being evaluated to reduce atherosclerotic cardiovascular disease risk. Lipoprotein apheresis (LA) is effective in acutely lowering the plasma concentrations of atherogenic lipoproteins including low-density lipoprotein cholesterol and lipoprotein(a), and novel lipid-lowering drugs may dampen the lipid rebound effect of LA, with the possibility that LA frequency may be decreased, in some cases even be discontinued. SOURCES OF MATERIAL: This document builds on current American Society for Apheresis guidelines and, for the first time, makes recommendations from summarized data of the emerging lipid-lowering drug classes (inhibitors of proprotein convertase subtilisin/kexin type 9 or microsomal triglyceride transfer protein, high-density lipoprotein mimetic), including the available evidence on combination therapy with LA with respect to the management of patients with dyslipidemia. ABSTRACT OF FINDINGS: Recommendations for different indications are given based on the latest evidence. However, except for lomitapide in homozygous familial hypercholesterolemia and alirocumab/ evolocumab in heterozygous familial hypercholesterolemia subjects, limited data are available on the effectiveness and safety of combination therapy. More studies on combining LA with novel lipid-lowering drugs are needed. CONCLUSION: Novel lipid-lowering agents have potential to improve the performance of LA, but more evidence is needed. The Multidisciplinary International Group for Hemapheresis TherapY and Metabolic DIsturbances Contrast scientific society aims to establish an international registry of clinical experience on LA combination therapy to expand the evidence on this treatment in individuals at high cardiovascular disease risk.

Toward an international consensus - integrating lipoprotein apheresis and new lipid-lowering drugs / Stefanutti, Claudia; Julius, Ulrich; Watts, Gerald F.; Harada shiba, Mariko; Cossu, Maria; Schettler, Volker J.; De Silvestro, Giustina; Soran, Handrean; Van Lennep, Jeanine Roeters; Pisciotta, Livia; Klã¶r, Hans U.; Widhalm, Kurt; Moriarty, Patrick M.; D'Alessandri, Giovanna; Bianciardi, Giorgio; Bosco, Giovanna; De Fusco, Giulia; DI GIACOMO, Serafina; Morozzi, Claudia; Mesce, Dario; Vitale, Marco; Sovrano, Barbara; Drogari, Euridiki; Ewald, Nils; Gualdi, Gianfranco; Jaeger, Beate R.; Lanti, Alessandro; Marson, Piero; Martino, Francesco; Migliori, Giuseppe; Parasassi, Tiziano; Pavan, Antonio; Perla, Francesco Massimo; Brunelli, Roberto; Perrone, Giuseppina; Renga, Salvatorica; Ries, Wolfgang; Romano, Nicola; Romeo, Stefano; Pergolini, Mario Sergio; Labbadia, Giancarlo; Di Iorio, Biagio; De Palo, Tommaso; Abbate, Rosanna; Marcucci, Rossella; Poli, Lorella; Ardissino, Gianluigi; Ottone, Piero; Tison, Tiziana; Favari, Elda; Borgese, Leonardo; Shafii, Manhaz; Gozzer, Maria; Pacella, Elena; Torromeo, Concetta; Parassassi, Tiziana; Berni, Andrea; Guardamagna, Ornella; Zenti, Maria Grazia; Guitarrini, Maria Rita; Berretti, Daniele; Hohenstein, Bernd; Saheb, Samir; Bjelakovic, Bojko; Williams, Helen; De Luca N, Null. - In: JOURNAL OF CLINICAL LIPIDOLOGY. - ISSN 1933-2874. - STAMPA. - 11:4(2017), pp. 858-871. [10.1016/j.jacl.2017.04.114]

Toward an international consensus - integrating lipoprotein apheresis and new lipid-lowering drugs

STEFANUTTI, Claudia
Primo
;
BOSCO, Giovanna;DI GIACOMO, SERAFINA;MOROZZI, CLAUDIA;VITALE, MARCO;GUALDI, GIANFRANCO;MARTINO, Francesco;PAVAN, Antonio;PERLA, Francesco Massimo;BRUNELLI, Roberto;PERRONE, Giuseppina;ROMEO, STEFANO;PERGOLINI, Mario Sergio;LABBADIA, Giancarlo;BORGESE, Leonardo;PACELLA, Elena;TORROMEO, Concetta;BERNI, Andrea;
2017

Abstract

BACKGROUND: Despite advances in pharmacotherapy of lipid disorders, many dyslipidemic patients do not attain sufficient lipid lowering to mitigate risk of atherosclerotic cardiovascular disease. Several classes of novel lipid-lowering agents are being evaluated to reduce atherosclerotic cardiovascular disease risk. Lipoprotein apheresis (LA) is effective in acutely lowering the plasma concentrations of atherogenic lipoproteins including low-density lipoprotein cholesterol and lipoprotein(a), and novel lipid-lowering drugs may dampen the lipid rebound effect of LA, with the possibility that LA frequency may be decreased, in some cases even be discontinued. SOURCES OF MATERIAL: This document builds on current American Society for Apheresis guidelines and, for the first time, makes recommendations from summarized data of the emerging lipid-lowering drug classes (inhibitors of proprotein convertase subtilisin/kexin type 9 or microsomal triglyceride transfer protein, high-density lipoprotein mimetic), including the available evidence on combination therapy with LA with respect to the management of patients with dyslipidemia. ABSTRACT OF FINDINGS: Recommendations for different indications are given based on the latest evidence. However, except for lomitapide in homozygous familial hypercholesterolemia and alirocumab/ evolocumab in heterozygous familial hypercholesterolemia subjects, limited data are available on the effectiveness and safety of combination therapy. More studies on combining LA with novel lipid-lowering drugs are needed. CONCLUSION: Novel lipid-lowering agents have potential to improve the performance of LA, but more evidence is needed. The Multidisciplinary International Group for Hemapheresis TherapY and Metabolic DIsturbances Contrast scientific society aims to establish an international registry of clinical experience on LA combination therapy to expand the evidence on this treatment in individuals at high cardiovascular disease risk.
BACKGROUND: Despite advances in pharmacotherapy of lipid disorders, many dyslipidemic patients do not attain sufficient lipid lowering to mitigate risk of atherosclerotic cardiovascular disease. Several classes of novel lipid-lowering agents are being evaluated to reduce atherosclerotic cardiovascular disease risk. Lipoprotein apheresis (LA) is effective in acutely lowering the plasma concentrations of atherogenic lipoproteins including low-density lipoprotein cholesterol and lipoprotein(a), and novel lipid-lowering drugs may dampen the lipid rebound effect of LA, with the possibility that LA frequency may be decreased, in some cases even be discontinued. SOURCES OF MATERIAL: This document builds on current American Society for Apheresis guidelines and, for the first time, makes recommendations from summarized data of the emerging lipid-lowering drug classes (inhibitors of proprotein convertase subtilisin/kexin type 9 or microsomal triglyceride transfer protein, high-density lipoprotein mimetic), including the available evidence on combination therapy with LA with respect to the management of patients with dyslipidemia. ABSTRACT OF FINDINGS: Recommendations for different indications are given based on the latest evidence. However, except for lomitapide in homozygous familial hypercholesterolemia and alirocumab/ evolocumab in heterozygous familial hypercholesterolemia subjects, limited data are available on the effectiveness and safety of combination therapy. More studies on combining LA with novel lipid-lowering drugs are needed. CONCLUSION: Novel lipid-lowering agents have potential to improve the performance of LA, but more evidence is needed. The Multidisciplinary International Group for Hemapheresis TherapY and Metabolic DIsturbances Contrast scientific society aims to establish an international registry of clinical experience on LA combination therapy to expand the evidence on this treatment in individuals at high cardiovascular disease risk.
File allegati a questo prodotto
File Dimensione Formato  
Stefanutti_Toward an international consensus_2017.pdf

accesso aperto

Note: https://www.sciencedirect.com/science/article/pii/S1933287417302489
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.79 MB
Formato Adobe PDF
1.79 MB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1011930
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 77
  • ???jsp.display-item.citation.isi??? 73
social impact